Skip to search formSkip to main contentSkip to account menu

darunavir

Known as: [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester, Darunavirum, {(1S,2R)-3-[(4-amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester 
An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone… 
National Institutes of Health

Related topics

Related topics

17 relations
Darunavir:MCnc:Pt:Ser/Plas:QnDarunavir:Susc:Pt:Isolate:OrdQn:PhenotypingHIV Protease Inhibitors [MoA]In Blood

Broader (1)

HIV Protease Inhibitors

Narrower (4)

PrezcobixTMC 114UIC-94017darunavir ethanolate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12…
2014
2014
French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults
These guidelines are part of the French Experts’ recommendations for the management of people living with HIV/AIDS, which were… 
2012
2012
Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement.
Highly Cited
2012
Highly Cited
2012
Origin of decrease in potency of darunavir and two related antiviral inhibitors against HIV-2 compared to HIV-1 protease.
Acquired immune deficiency syndrome (AIDS) is caused by the human immunodeficiency virus (HIV) type 1 and 2 (HIV-1 and HIV-2… 
Review
2011
Review
2011
Efficacy of new antiretroviral drugs in treatment‐experienced HIV‐infected patients: a systematic review and meta‐analysis of recent randomized controlled trials
We performed a systematic review and meta‐analysis of randomized controlled trials (RCTs) to assess the overall efficacy of new… 
2011
2011
HIV-1 group N: travelling beyond Cameroon
Review
2011
Review
2011
Merkel cell carcinoma associated with HIV: review of 14 patients.
Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine tumor that has a high propensity for early metastases and high… 
2009
2009
Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass…
Highly Cited
2009
Highly Cited
2009
Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection
Background:Boosted darunavir (DRV/r) plus etravirine (ETR), in DUET trials, and raltegravir, in BENCHMRK trials, showed high… 
Highly Cited
2008
Highly Cited
2008
A Potent HIV Protease Inhibitor, Darunavir, Does Not Inhibit ZMPSTE24 or Lead to an Accumulation of Farnesyl-prelamin A in Cells*
HIV protease inhibitors (HIV-PIs) are key components of highly active antiretroviral therapy, but they have been associated with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)